Full text is available at the source.
Abstract
Tirzepatide was approved by the FDA for type 2 diabetes mellitus in 2022 and for chronic weight management in 2023.
- Tirzepatide is a dual receptor agonist targeting GIP and GLP-1.
- The efficacy of tirzepatide in clinical trials was notably superior compared to other treatments.
- Real-world safety data for tirzepatide is not fully established.
- The study focused on analyzing safety signals from the FAERS database.
Simplified